Henry Davies
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Henry Davies has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
D. Julian A. Scott
4 shared publications- David Alexander Russell
Leeds Vascular Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
4 shared publications - Barend Mathijs Eduard Mees
Department of Vascular Surgery, Maastricht University Medical Centre, The Netherlands
3 shared publications Jing Yi Kwan
3 shared publicationsAnahita Dua
2 shared publicationsAssad Khan
Leeds General Infirmary , Great George Street, Leeds LS1 3EX
2 shared publications
Latest Publications
- Open Access
Revascularisation versus amputation for chronic limb-threatening ischaemia: a systematic review and meta-analysis of clinical outcomes and patient characteristics
Background: The relative merits of infrainguinal bypass and primary major lower limb amputation (MLLA) for chronic limb-threatening ischaemia (CLTI) remain uncertain, and the baseline profiles of patients selected for each strategy are poorly described. Methods: A systematic review and meta-analysis were undertaken in accordance with PRISMA 2020 and prospectively registered (PROSPERO: CRD42022356094). MEDLINE, Embase, CENTRAL, and CINAHL were searched from inception to March 2025. Prospective studies of adults with CLTI undergoing primary infrainguinal bypass or primary MLLA were eligible. Mortality, major adverse cardiovascular events (MACE) and subsequent amputation outcomes were synthesised using random-effects meta-analysis of proportions. Baseline comorbidity profiles were also extracted. Results: Twenty-seven studies involving 6,576 patients were included: 5,779 underwent infrainguinal bypass and 797 underwent MLLA. After bypass, pooled mortality was 3.7% at 30 days (95% CI 2.8%–4.9%, I² = 49.4%), 18.5% at 1 year (95% CI 15.6%–21.9%, I² = 62.3%), and 54.3% at 5 years (95% CI 50.5%–58.0%, I² = 0%). After MLLA, pooled mortality was 9.2% at 30 days (95% CI 4.1%–19.3%, I² = 73.5%), 28.5% at 1 year (95% CI 13.3%–51.0, I² = 70.8%), and 39.9% at 2 years (95% CI 0.3%–99.3, I² = 90.5%), although longer-term estimates were limited by sparse data and marked heterogeneity. Thirty-day MACE was 6.5% (95% CI 4.3%–9.7, I² = 63.5%) after bypass and 2.8% after MLLA (95% CI 0.1%–37.6%, I² = 0%). Early subsequent major amputation after bypass occurred in 3.9% of patients (95% CI 2.0%–7.7%, I² = 91.2%), rising to 16.2% at 1 year (95% CI 12.6%–20.5%, I² = 82.0%) and 33.3% at 3 years (95% CI 20.1%–49.8%, I² = 0%). Early re-amputation after MLLA occurred in 10.9% of patients (95% CI 4.5%–24.4%, I² = 40.3%). Baseline comorbidity burden was high in both groups, with substantial heterogeneity across studies. Conclusions: CLTI carries a poor prognosis regardless of treatment strategy. Infrainguinal bypass is associated with lower early mortality and better early limb preservation than primary MLLA, but long-term survival remains poor and later limb failure is common. Primary MLLA is not a low-risk alternative. Better contemporary comparative evidence utilising modern causal inference approaches is needed to support individualised decision-making.
Open AccessRevascularisation versus amputation for chronic limb-threatening ischaemia: a systematic review and meta-analysis of clinical outcomes and patient characteristics
Background: The relative merits of infrainguinal bypass and primary major lower limb amputation (MLLA) for chronic limb-threatening ischaemia (CLTI) remain uncertain, and the baseline profiles of patients selected for each strategy are poorly described. Methods: A systematic review and meta-analysis were undertaken in accordance with PRISMA 2020 and prospectively registered (PROSPERO: CRD42022356094). MEDLINE, Embase, CENTRAL, and CINAHL were searched from inception to March 2025. Prospective studies of adults with CLTI undergoing primary infrainguinal bypass or primary MLLA were eligible. Mortality, major adverse cardiovascular events (MACE) and subsequent amputation outcomes were synthesised using random-effects meta-analysis of proportions. Baseline comorbidity profiles were also extracted. Results: Twenty-seven studies involving 6,576 patients were included: 5,779 underwent infrainguinal bypass and 797 underwent MLLA. After bypass, pooled mortality was 3.7% at 30 days (95% CI 2.8%–4.9%, I² = 49.4%), 18.5% at 1 year (95% CI 15.6%–21.9%, I² = 62.3%), and 54.3% at 5 years (95% CI 50.5%–58.0%, I² = 0%). After MLLA, pooled mortality was 9.2% at 30 days (95% CI 4.1%–19.3%, I² = 73.5%), 28.5% at 1 year (95% CI 13.3%–51.0, I² = 70.8%), and 39.9% at 2 years (95% CI 0.3%–99.3, I² = 90.5%), although longer-term estimates were limited by sparse data and marked heterogeneity. Thirty-day MACE was 6.5% (95% CI 4.3%–9.7, I² = 63.5%) after bypass and 2.8% after MLLA (95% CI 0.1%–37.6%, I² = 0%). Early subsequent major amputation after bypass occurred in 3.9% of patients (95% CI 2.0%–7.7%, I² = 91.2%), rising to 16.2% at 1 year (95% CI 12.6%–20.5%, I² = 82.0%) and 33.3% at 3 years (95% CI 20.1%–49.8%, I² = 0%). Early re-amputation after MLLA occurred in 10.9% of patients (95% CI 4.5%–24.4%, I² = 40.3%). Baseline comorbidity burden was high in both groups, with substantial heterogeneity across studies. Conclusions: CLTI carries a poor prognosis regardless of treatment strategy. Infrainguinal bypass is associated with lower early mortality and better early limb preservation than primary MLLA, but long-term survival remains poor and later limb failure is common. Primary MLLA is not a low-risk alternative. Better contemporary comparative evidence utilising modern causal inference approaches is needed to support individualised decision-making.
- Open Access
- 15 July 2026
- Published by Elsevier in SSRN Electronic Journal
Industry Sponsorship and Reported Outcomes in Arterial Vascular Surgery Randomised Trials: A Meta-Research Analysis (VISION Study)
Background: Industry funding has been associated with favourable trial outcomes across several areas of medicine, but whether this association exists in arterial vascular surgery is unclear. We evaluated the association between industry sponsorship and reported primary outcome direction in major arterial vascular randomised controlled trials.Methods: We conducted a cross-sectional meta-research analysis of 60 arterial vascular randomised controlled trials meeting predefined eligibility criteria. Extracted variables included funding source; trial design; non-inferiority margin reporting; and primary outcome direction. Fisher's exact testing and logistic regression were used to evaluate the association between industry sponsorship and the likelihood of a positive primary outcome. A positive outcome was prespecified as superiority or non-inferiority of the newer or higher-cost intervention compared with the control, according to the stated trial design.Findings: Of 60 randomised trials included, 59 contributed to the primary outcome analysis, comprising 32 industry-funded, 22 non-industry-funded, three mixed-funded and two trials with unknown funding. Industry-funded trials were more likely to report positive primary outcomes than all other trials (78% vs 26%; Fisher's exact test: OR 9.7, 95% CI 2.68–41; p<0.001). Logistic regression demonstrated similar findings (OR 10.2, 95% CI 3.24–36; p<0.001). The association remained consistent in sensitivity analyses excluding studies with mixed and unknown funding status. Among seven non-inferiority trials, three of five industry-funded trials reported a predefined numerical non-inferiority margin before trial commencement, whereas both the non-industry-funded and mixed-funded non-inferiority trials reported predefined margins.Interpretation: Industry sponsorship was strongly associated with favourable primary outcomes in arterial vascular randomised controlled trials. Although the mechanisms underlying this association cannot be determined from this study, the findings support greater transparency in trial funding, prospective reporting of non-inferiority methodology and independent methodological oversight to strengthen the integrity, reproducibility and interpretation of the arterial vascular evidence base.
- 15 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIndustry Sponsorship and Reported Outcomes in Arterial Vascular Surgery Randomised Trials: A Meta-Research Analysis (VISION Study)
Background: Industry funding has been associated with favourable trial outcomes across several areas of medicine, but whether this association exists in arterial vascular surgery is unclear. We evaluated the association between industry sponsorship and reported primary outcome direction in major arterial vascular randomised controlled trials.Methods: We conducted a cross-sectional meta-research analysis of 60 arterial vascular randomised controlled trials meeting predefined eligibility criteria. Extracted variables included funding source; trial design; non-inferiority margin reporting; and primary outcome direction. Fisher's exact testing and logistic regression were used to evaluate the association between industry sponsorship and the likelihood of a positive primary outcome. A positive outcome was prespecified as superiority or non-inferiority of the newer or higher-cost intervention compared with the control, according to the stated trial design.Findings: Of 60 randomised trials included, 59 contributed to the primary outcome analysis, comprising 32 industry-funded, 22 non-industry-funded, three mixed-funded and two trials with unknown funding. Industry-funded trials were more likely to report positive primary outcomes than all other trials (78% vs 26%; Fisher's exact test: OR 9.7, 95% CI 2.68–41; p<0.001). Logistic regression demonstrated similar findings (OR 10.2, 95% CI 3.24–36; p<0.001). The association remained consistent in sensitivity analyses excluding studies with mixed and unknown funding status. Among seven non-inferiority trials, three of five industry-funded trials reported a predefined numerical non-inferiority margin before trial commencement, whereas both the non-industry-funded and mixed-funded non-inferiority trials reported predefined margins.Interpretation: Industry sponsorship was strongly associated with favourable primary outcomes in arterial vascular randomised controlled trials. Although the mechanisms underlying this association cannot be determined from this study, the findings support greater transparency in trial funding, prospective reporting of non-inferiority methodology and independent methodological oversight to strengthen the integrity, reproducibility and interpretation of the arterial vascular evidence base.
- 29 April 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (5) , 925-926
Education and behavioural change as part of exercise programmes for patients with peripheral arterial disease
- 29 April 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (5) , 925-926
Education and behavioural change as part of exercise programmes for patients with peripheral arterial disease
- Open Access
- 10 March 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (2)
Analgesic strategies for ischaemic pain in chronic limb–threatening ischaemia: a systematic review and meta-analysis
To evaluate the effectiveness of pharmacological (eg, ketamine, lidocaine) and nonpharmacological (eg, spinal cord stimulation, mononuclear cell therapy) analgesic strategies—outside the WHO pain ladder—for patients with chronic limb–threatening ischaemia (CLTI). A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines, searching 5 electronic databases for studies evaluating analgesia in CLTI. Both randomised and nonrandomised studies were included. Standardised mean differences (SMDs) in post-treatment pain scores were extracted or calculated, and random-effects meta-analyses performed for comparable studies. Twenty-one studies met inclusion criteria. Most investigated mononuclear cell therapy, hepatocyte growth factor, or prostaglandin infusions. Meta-analyses of mononuclear cell therapy vs standard treatment at 3 months showed significant benefit (3 studies; SMD = −2.12, 95% confidence interval [CI] −3.19 to −1.05, P = 0.001, I 2 = 86.95%). At 6 months, benefit persisted (3 studies; SMD = −2.54, 95% CI −3.95 to −1.14, P = 0.0004, I 2 = 92.0%). Across studies, mononuclear cell therapy showed the largest effect sizes but was associated with high heterogeneity and, due to restrictive exclusion criteria, had limited generalisability and poor practicality. Hepatocyte growth factor therapy showed a nonsignificant trend towards pain reduction, and prostaglandin infusion demonstrated no meaningful effect; both excluded large proportions of the CLTI cohort. Of the single-study interventions, subcutaneous lidocaine and ketamine provided short-term analgesic benefit with acceptable safety, whereas others did not produce statistically significant improvements. Pharmacological management of pain in CLTI remains challenging. No recommendations can be made for agents outside standard care. Several novel approaches, including ketamine and subcutaneous lidocaine, warrant further investigation. Further research into novel analgesics for CLTI is urgently needed.
- 10 March 2026
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 11 (2)
Open AccessAnalgesic strategies for ischaemic pain in chronic limb–threatening ischaemia: a systematic review and meta-analysis
To evaluate the effectiveness of pharmacological (eg, ketamine, lidocaine) and nonpharmacological (eg, spinal cord stimulation, mononuclear cell therapy) analgesic strategies—outside the WHO pain ladder—for patients with chronic limb–threatening ischaemia (CLTI). A systematic review and meta-analysis was conducted in accordance with PRISMA guidelines, searching 5 electronic databases for studies evaluating analgesia in CLTI. Both randomised and nonrandomised studies were included. Standardised mean differences (SMDs) in post-treatment pain scores were extracted or calculated, and random-effects meta-analyses performed for comparable studies. Twenty-one studies met inclusion criteria. Most investigated mononuclear cell therapy, hepatocyte growth factor, or prostaglandin infusions. Meta-analyses of mononuclear cell therapy vs standard treatment at 3 months showed significant benefit (3 studies; SMD = −2.12, 95% confidence interval [CI] −3.19 to −1.05, P = 0.001, I 2 = 86.95%). At 6 months, benefit persisted (3 studies; SMD = −2.54, 95% CI −3.95 to −1.14, P = 0.0004, I 2 = 92.0%). Across studies, mononuclear cell therapy showed the largest effect sizes but was associated with high heterogeneity and, due to restrictive exclusion criteria, had limited generalisability and poor practicality. Hepatocyte growth factor therapy showed a nonsignificant trend towards pain reduction, and prostaglandin infusion demonstrated no meaningful effect; both excluded large proportions of the CLTI cohort. Of the single-study interventions, subcutaneous lidocaine and ketamine provided short-term analgesic benefit with acceptable safety, whereas others did not produce statistically significant improvements. Pharmacological management of pain in CLTI remains challenging. No recommendations can be made for agents outside standard care. Several novel approaches, including ketamine and subcutaneous lidocaine, warrant further investigation. Further research into novel analgesics for CLTI is urgently needed.
- 12 February 2026
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 127, 195-200
Pain Management in Chronic Limb-Threatening Ischemia: A Multicentre Cross-Sectional Study
- 12 February 2026
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 127, 195-200
Pain Management in Chronic Limb-Threatening Ischemia: A Multicentre Cross-Sectional Study
- 3 January 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Vascular-POPS: evidence for a new standard of care in the management of chronic limb-threatening Ischaemia
Objective: Patients with chronic limb-threatening ischaemia (CLTI) are often admitted emergently with significant comorbidity and frailty, and little time for pre-optimisation, resulting in longer hospital stays and worse outcomes. Our unit implemented a POPS (Perioperative Medicine for the Older Person undergoing Surgery) service, incorporating the comprehensive geriatric assessment (CGA) to optimise patients. This study assesses its effect on non-elective CLTI inpatients. Methods: This is a prospective observational cohort study at a single vascular centre, analysing outcomes in non-elective CLTI patients over three different periods: one year prior to POPS (‘Pre-POPS’); during the initial delivery when it was nurse-led (‘POPS v1’); and after it became physician-led (‘POPS v2’). The primary outcome was length of stay (LoS), with 30-day and 12-month secondary outcomes. Cohorts were compared using propensity-score weighted statistical analysis. Economic analysis was undertaken. Results: Six hundred and two patients were included. LoS reduced sequentially with greater POPS input (17 days vs. 13 days vs. 11 days, P < .001). There was a significant reduction in 30-day acute kidney injury (33% vs. 37% vs. 8%, P < .001), myocardial infarction (15% vs. 2% vs. 2% P < .001) and hospital-acquired pneumonia (17% vs. 10% vs. 9%, P = .048). Cox survival regression found a reduction in 12-month mortality of 37% for the POPS v1 [HR 0.628 (95% CI 0.481–0.891) P = .013] and 40% for the POPS v2 [HR 0.598 (95% CI 0.431–0.913) P = .001] cohorts, respectively. Economic analysis found that handling more medically complex patients with a shorter LoS negated its operational costs. Conclusion: A Vascular-POPS collaborative service has resulted in major improvements in LoS, adverse events and survival in this most vulnerable of vascular patient cohorts and is a financially sustainable initiative.
- 3 January 2026
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 55 (1)
Vascular-POPS: evidence for a new standard of care in the management of chronic limb-threatening Ischaemia
Objective: Patients with chronic limb-threatening ischaemia (CLTI) are often admitted emergently with significant comorbidity and frailty, and little time for pre-optimisation, resulting in longer hospital stays and worse outcomes. Our unit implemented a POPS (Perioperative Medicine for the Older Person undergoing Surgery) service, incorporating the comprehensive geriatric assessment (CGA) to optimise patients. This study assesses its effect on non-elective CLTI inpatients. Methods: This is a prospective observational cohort study at a single vascular centre, analysing outcomes in non-elective CLTI patients over three different periods: one year prior to POPS (‘Pre-POPS’); during the initial delivery when it was nurse-led (‘POPS v1’); and after it became physician-led (‘POPS v2’). The primary outcome was length of stay (LoS), with 30-day and 12-month secondary outcomes. Cohorts were compared using propensity-score weighted statistical analysis. Economic analysis was undertaken. Results: Six hundred and two patients were included. LoS reduced sequentially with greater POPS input (17 days vs. 13 days vs. 11 days, P < .001). There was a significant reduction in 30-day acute kidney injury (33% vs. 37% vs. 8%, P < .001), myocardial infarction (15% vs. 2% vs. 2% P < .001) and hospital-acquired pneumonia (17% vs. 10% vs. 9%, P = .048). Cox survival regression found a reduction in 12-month mortality of 37% for the POPS v1 [HR 0.628 (95% CI 0.481–0.891) P = .013] and 40% for the POPS v2 [HR 0.598 (95% CI 0.431–0.913) P = .001] cohorts, respectively. Economic analysis found that handling more medically complex patients with a shorter LoS negated its operational costs. Conclusion: A Vascular-POPS collaborative service has resulted in major improvements in LoS, adverse events and survival in this most vulnerable of vascular patient cohorts and is a financially sustainable initiative.
- Open Access
- 31 December 2025
- Published by Elsevier in EJVES Vascular Forum
- Vol. 65, 43-48
Clinician Attitudes towards Analgesia for Chronic Limb Threatening Ischaemia: A Survey of Vascular Specialists to Inform a Topical Morphine Trial
- 31 December 2025
- Published by Elsevier in EJVES Vascular Forum
- Vol. 65, 43-48
Open AccessClinician Attitudes towards Analgesia for Chronic Limb Threatening Ischaemia: A Survey of Vascular Specialists to Inform a Topical Morphine Trial
- Open Access
- 30 September 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 2
End of life care in chronic limb threatening ischemia: A retrospective cohort study
- 30 September 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 2
Open AccessEnd of life care in chronic limb threatening ischemia: A retrospective cohort study
- Open Access
- 3 May 2024
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (5)
End of life care in vascular surgery
Historically, vascular surgery has been associated with a lack of holistic care or insufficient consideration for non-operative management. In part, these observations stem from the fact that many vascular conditions are rapidly progressive in nature and usually exist in patients with a high burden of co-morbidity and frailty.
- 3 May 2024
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 111 (5)
Open AccessEnd of life care in vascular surgery
Historically, vascular surgery has been associated with a lack of holistic care or insufficient consideration for non-operative management. In part, these observations stem from the fact that many vascular conditions are rapidly progressive in nature and usually exist in patients with a high burden of co-morbidity and frailty.
- 16 October 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 99, 280-289
End of Life Care for Unplanned Vascular Admissions
- 16 October 2023
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 99, 280-289
End of Life Care for Unplanned Vascular Admissions